Abstract：OBJECTIVE: To evaluate the efficacy and safety of radix astragali and its compound prescription for treatment of β-thalassemia in children. METHODS: This study was a randomized, controlled, double-blind clinical trial. Fifty-seven children with β-thalassemia were randomly assigned to radix astragali, compound prescription (radix astragali+ codonopsis pilosula + tortoise plastron) and placebo control groups after stratifying the patients according to disease type (intermedia and major). The parameters of hematology and safety were assessed after 12 weeks of treatment. RESULTS: After 12 weeks of treatment, the mean Hb elevation levels in children with β-thalassemia intermedia from the compound prescription and the radix astragali groups were 1.21±1.12 and 1.05±0.80 g/dL respectively compared with -(0.28±0.51) g/dL in the placebo control group (P<0.01). Mean Hb levels in the compound prescription and radix astragali groups were significantly higher than in the placebo control group (P<0.05). Therapy with both radix astragali and its compound prescription increased fetal hemoglobin, red blood cell, mean corpuscular hemoglobin and reticulocyte levels in children with β-thalassemia intermedia. The total effective rates were 64% and 62% in children with β-thalassemia intermedia from the compound prescription and radix astragali groups respectively, which was significantly higher than in the placebo control group (9%; P<0.01). Therapy with radix astragali or its compound prescription in children with β-thalassemia major had similar but less favourable effets than the same therapy in children with β-thalassemia intermedia. White blood cell, neutrophil, platelet and hepatic and renal functions were not adversely affected by the medicines. CONCLUSIONS: Therapy with radix astragali or its compound prescription is effective and safe in children with β-thalassemia.
LU Zhuo-Ming,QIAN Xin-Hua,CHEN Zhi-Wen et al. Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children[J]. CJCP, 2012, 14(5): 344-349.
［1］Rund D, Rachmilewitz E. Beta-thalassemia ［J］. N Engl J Med, 2005, 353(11): 1135-1146.
［2］Weatherall DJ. Keynote address: the challenge of thalassemia for the developing countries［J］. Ann NY Acad Sci, 2005, 1054: 11-17.
［3］Thein SL, Menzel S, Lathrop M, Garner C. Control of fetal hemoglobin: new insights emerging from genomics and clinical implications［J］. Hum Mol Genet, 2009, 18(R2): R216-R223.
［4］Perrine SP. Fetal globin induction-can it cure beta thalassemia?［J］. Hematology, Am Soc Hematol Educ Program, 2005, 38-44.
［10］Yang M, Qian XH, Zhao DH, Fu SZ. Effects of Astragalus polysaccharide on the erythroid lineage and microarray analysis in K562 cells ［J］. J Ethnopharmacol, 2010, 127(2): 242250.
［11］张之南，沈悌. 血液病诊断及疗效标准 ［M］. 北京:科学出版社, 2007:29-30.
［12］Xu XM, Zhou YQ, Lou GX, Liao C, Zhou M, Chen PY, et al. The prevalence and spectrum of alpha and beta thalassaemia in Guangdong Province: implications for the future health burden and population screening［J］. J Clin Pathol, 2004, 57(5): 517-522.
［15］Muncie HL Jr, Campbell J. Alpha and beta thalassemia［J］. Am Fam Physician, 2009, 80(4): 339-441.
［16］Vichinsky E. Oral iron chelators and the treatment of iron overload in pediatric patients with chronic anemia ［J］. Pediatrics, 2008, 121(6): 1253-1256.
［17］Walters MC. Gene therapy and bone marrow transplantation for thalassemia: changing of the guard?［J］. Mol Ther, 2010, 18(9): 1577.
［18］Pace BS, Zein S. Understanding mechanisms of gamma-globin gene regulation to develop strategies for pharmacological fetal hemoglobin induction［J］. Dev Dyn, 2006, 235(7): 1727-1737.
